Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pathfinder™7: PK of Turoctocog Alfa Pegol in Haemophilia A
NCT02920398Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2016
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 1, randomised, open-label trial of turoctocog alfa pegol in hemophilia A (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the FVIII activity-time curve. Started Oct 2016; status: completed.
02
Drugs
turoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02920398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920398.